Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE)

Historical Holders from Q2 2021 to Q3 2025

Symbol
GLUE on Nasdaq
CUSIP
61225M102
Type / Class
Equity / COMMON STOCK
Shares outstanding
61.8M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
60M
Holdings value
$445M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
124
Number of buys
57
Number of sells
-54
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 9.2% +28.6% $23.9M $5.35M 5.66M +28.8% BVF PARTNERS L P/IL Mar 31, 2025
Dimension Capital I, L.P. 7.7% $23M 4.76M Adam Goulburn May 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/ 7.5% $34.4M 4.64M T. Rowe Price Associates, Inc. Sep 30, 2025
TCG Crossover GP II, LLC 7.2% $32.8M 4.43M Chen Yu Oct 10, 2025
BlackRock, Inc. 6.3% $16.2M 3.84M BlackRock, Inc. Dec 31, 2024
SUVRETTA CAPITAL MANAGEMENT, LLC 5.5% $14.2M 3.36M SUVRETTA CAPITAL MANAGEMENT, LLC Apr 9, 2025
Versant Venture Capital VI, L.P. 5.1% $24.7M 3.33M Versant Venture Capital VI, L.P. Nov 10, 2025
VANGUARD GROUP INC 4.83% -6% $22.1M -$1.24M 2.99M -5.3% The Vanguard Group Sep 30, 2025
FMR LLC 2.8% $7.07M 1.75M FMR LLC May 30, 2025

Institutional Holders of Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 60M $445M -$4.39M $7.41 124
2025 Q2 62.2M $281M +$12M $4.51 115
2025 Q1 59.5M $276M -$11.9M $4.64 105
2024 Q4 61M $423M +$79.1M $6.94 104
2024 Q3 49.8M $264M +$18.2M $5.30 81
2024 Q2 45.8M $171M +$22M $3.74 74
2024 Q1 39.9M $281M -$271K $7.05 67
2023 Q4 12.5K $70.4K -$454K $5.65 1
2023 Q3 42M $201M +$10.9M $4.79 72
2023 Q2 39.7M $272M -$3.2M $6.85 68
2023 Q1 39.8M $310M -$11.1M $7.79 69
2022 Q4 41.2M $314M +$7.27M $7.61 65
2022 Q3 40.2M $328M -$4.08M $8.17 67
2022 Q2 38.8M $375M -$12M $9.67 53
2022 Q1 39.9M $560M +$42M $14.02 52
2021 Q4 36.3M $742M +$28.4M $20.42 53
2021 Q3 34.9M $759M +$62.1M $22.28 55
2021 Q2 32.1M $705M +$705M $22.70 48